Stroke resulted in an almost 3-fold decrease in CFSE-positive CD4+CD3+T cells, whereas treatment with ML-193, a GRP55 antagonist, attenuated T-cell egress from the spleen by 62% ± 7% (Figure 4). This evidence concerns the gene CD4 and stroke disorder.